StreetInsider.com News Articles

Alcon rises on profit guidance hike, lowered tariff impact estimate

Tue, 11 Aug 2026 06:51:11 -0400

Investing.com -- Alcon lifted its full-year profit guidance late Monday and lowered its estimate for the annual tariff impact to $40 million to $90 million, from a prior range of $100 million to $150 million, factoring in an anticipated refund of around $60 million from the U.S. government.

The U.S. accounted for 45% of Alcon’s net sales in the first half of the year, and most of the company’s major production facilities are located there.

Shares rose more than 3% by 08:24 GMT.

The Swiss-American eye care company now expects its core operating profit margin to rise 90 to 190 basis points in

Alcon rises on profit guidance hike, lowered tariff impact estimate

Tue, 11 Aug 2026 06:51:11 -0400

The U.S. accounted for 45% of Alcon’s net sales in the first half of the year, and most of the company’s major production facilities are located there.

Shares rose more than 3% by 08:24 GMT.

The Swiss-American eye care company now expects its core operating profit margin to rise 90 to 190 basis points in

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

Investing.com -- The monthslong tug-of-war for the future of STAAR Surgical Company (NASDAQ:STAA) ended Tuesday with a white flag. After four shareholder meeting postponements and a bitter proxy battle, the implantable lensmaker announced its intention to terminate its merger agreement with Swiss eye care giant Alcon AG (NYSE:ALC) after failing to secure enough shareholder support.

The collapse comes despite aggressive last-minute efforts by Alcon and STAAR leadership to entice a skeptical investor base. Over the last quarter, the companies increased the bid to $30.75 per share, initiated a "go-shop"

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%

Tue, 06 Jan 2026 11:58:27 -0400

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

Investing.com -- The protracted, $1.6 billion dollar saga over STAAR Surgical Company (NASDAQ:STAA) is entering its final, chaotic phase with the acquisition by Alcon AG (NYSE:ALC) now hinged on a deeply fractured shareholder vote on December 19. The market’s uncertainty peaked Tuesday after leading independent proxy advisory firm Institutional Shareholder Services (ISS) issued its recommendation, casting doubt on whether the controversial merger will pass with shareholders.

While the STAAR board announced late Monday that ISS had recommended a "FOR" vote on the raised $30.75 per share deal, activist shareholder Broadwood Partners immediately seized on the fine print, noting ISS also

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

ISS recommends STAAR Surgical deal, but warns shareholders have reason to object

Tue, 16 Dec 2025 16:06:37 -0400

STAAR Surgical falls as Yunqi Capital reiterates opposition to merger with Alcon